The Vaxxinity development pipeline is derived from our innovative, proprietary, proven synthetic peptide platform, which has allowed us to develop the first multitope peptide-based vaccine for COVID-19, as well as a new class of medicines for neurological diseases like Alzheimer’s and Parkinson’s with novel targets, and common chronic diseases like migraine and hyptercholesterolemia based on well validated targets. We call vaccine candidates based on our platform “Vaxxines.”